HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 2005-0090v1 23/9/1378    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silberstein, L. Articles by Göttgens, B. Search for Related Content PubMed PubMed Citation Articles by Silberstein, L. Articles by Göttgens, B.

Transgenic Analysis of the Stem Cell Leukemia +19 Stem Cell Enhancer in Adult and Embryonic Hematopoietic and Endothelial Cells

^a Department of Hematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom;
^b Centro Andaluz de Biologia del Desarrollo, Universidad Pablo de Olavide, Seville, Spain;
^c University of Massachusetts Medical School, Department of Pediatrics (Hematology/Oncology Division) and Department of Cancer Biology, Worcester, Massachusetts, USA;
^d The Laboratory of Lymphocyte Signaling and Development, The Babraham Institute, Babraham, Cambridge, United Kingdom

Key Words. Hematopoietic stem cell • Transcription factor SCL/tal-1 • Transcriptional regulation • Experimental models

Correspondence: Berthold Göttgens, D.Phil., Department of Hematology, Cambridge Institute for Medical Research, Cambridge University, Hills Road, Cambridge CB2 2XY, U.K. Telephone: 44-1223-336829; Fax: 44-1223-762670; e-mail: bg200{at}cam.ac.uk

Appropriate transcriptional regulation is critical for the biological functions of many key regulatory genes, including the stem cell leukemia (SCL) gene. As part of a systematic dissection of SCL transcriptional regulation, we have previously identified a 5,245-bp SCL +18/19 enhancer that targeted embryonic endothelium together with embryonic and adult hematopoietic progenitors and stem cells (HSCs). This enhancer is proving to be a powerful tool for manipulating hematopoietic progenitors and stem cells, but the design and interpretation of such transgenic studies require a detailed understanding of enhancer activity in vivo. In this study, we demonstrate that the +18/19 enhancer is active in mast cells, megakaryocytes, and adult endothelium. A 644-bp +19 core enhancer exhibited similar temporal and spatial activity to the 5,245-bp +18/19 fragment both during development and in adult mice. Unlike the +18/19 enhancer, the +19 core enhancer was only active in adult mice when linked to the eukaryotic reporter gene human placental alkaline phosphatase. Activity of a single core enhancer in HSCs, endothelium, mast cells, and megakaryocytes suggests possible overlaps in their respective transcriptional programs. Moreover, activity in a proportion of thymocytes and other SCL-negative cell types suggests the existence of a silencer elsewhere in the SCL locus.

This article has been cited by other articles:

				A. M. Smith, M.-J. Sanchez, G. A. Follows, S. Kinston, I. J. Donaldson, A. R. Green, and B. Gottgens A novel mode of enhancer evolution: The Tal1 stem cell enhancer recruited a MIR element to specifically boost its activity Genome Res., September 1, 2008; 18(9): 1422 - 1432. [Abstract] [Full Text] [PDF]

				J. Sausville, A. A. Molinolo, X. Cheng, J. Frampton, N. Takebe, J. S. Gutkind, and R. A. Feldman RCAS/SCL-TVA Animal Model Allows Targeted Delivery of Polyoma Middle T Oncogene to Vascular Endothelial Progenitors In vivo and Results in Hemangioma Development Clin. Cancer Res., June 15, 2008; 14(12): 3948 - 3955. [Abstract] [Full Text] [PDF]

				J.-R. Landry, S. Kinston, K. Knezevic, M. F.T.R. de Bruijn, N. Wilson, W. T. Nottingham, M. Peitz, F. Edenhofer, J. E. Pimanda, K. Ottersbach, et al. Runx genes are direct targets of Scl/Tal1 in the yolk sac and fetal liver Blood, March 15, 2008; 111(6): 3005 - 3014. [Abstract] [Full Text] [PDF]

				S. Ogilvy, R. Ferreira, S. G. Piltz, J. M. Bowen, B. Gottgens, and A. R. Green The SCL +40 Enhancer Targets the Midbrain Together with Primitive and Definitive Hematopoiesis and Is Regulated by SCL and GATA Proteins Mol. Cell. Biol., October 15, 2007; 27(20): 7206 - 7219. [Abstract] [Full Text] [PDF]

				E. Bockamp, C. Antunes, M. Maringer, R. Heck, K. Presser, S. Beilke, S. Ohngemach, R. Alt, M. Cross, R. Sprengel, et al. Tetracycline-controlled transgenic targeting from the SCL locus directs conditional expression to erythrocytes, megakaryocytes, granulocytes, and c-kit-expressing lineage-negative hematopoietic cells Blood, September 1, 2006; 108(5): 1533 - 1541. [Abstract] [Full Text] [PDF]

				L. R. Mollica, J. T. B. Crawley, K. Liu, J. B. Rance, P. N. Cockerill, G. A. Follows, J.-R. Landry, D. J. Wells, and D. A. Lane Role of a 5'-enhancer in the transcriptional regulation of the human endothelial cell protein C receptor gene Blood, August 15, 2006; 108(4): 1251 - 1259. [Abstract] [Full Text] [PDF]

				J. E. Pimanda, L. Silberstein, M. Dominici, B. Dekel, M. Bowen, S. Oldham, A. Kallianpur, S. J. Brandt, D. Tannahill, B. Gottgens, et al. Transcriptional Link between Blood and Bone: the Stem Cell Leukemia Gene and Its +19 Stem Cell Enhancer Are Active in Bone Cells. Mol. Cell. Biol., April 1, 2006; 26(7): 2615 - 2625. [Abstract] [Full Text] [PDF]